All In Biotech

Free tool

FAERS Monitor: Terlivaz

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022231 or its brand name (Terlivaz, Terlipressin Acetate). Reports on generic versions are filed under their own applications.

Reports

331

Serious

299

90% of reports

Hospitalization

147

Death reported

95

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective41
  • ascites25
  • diarrhoea23
  • renal impairment20
  • off label use18
  • acute kidney injury17
  • electrocardiogram qt prolonged17
  • multiple organ dysfunction syndrome17
  • product use in unapproved indication17
  • respiratory failure17
  • hepatic encephalopathy16
  • toxicity to various agents16
  • pulmonary oedema14
  • drug interaction12
  • hepatic failure12

Reports by year received

View as table
YearReports
20041
20055
20066
20081
20093
20103
20115
20128
20132
201414
201513
20165
20173
20189
201917
202026
202126
202229
202322
202424
202553
202656

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,828 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hepatic encephalopathySignal16109.167.61,606
ascitesSignal2554.137.11,251
multiple organ dysfunction syndromeSignal1738.224.0579
electrocardiogram qt prolongedSignal1730.018.9449
hepatic failureSignal1225.314.5257
pulmonary oedemaSignal1419.911.9233
renal impairmentSignal2015.19.9251
respiratory failureSignal1714.89.3206
acute kidney injurySignal177.14.483
toxicity to various agentsSignal166.03.763
drug interactionSignal124.82.833
product use in unapproved indicationSignal174.42.741
diarrhoeaSignal232.31.515
drug ineffective412.01.520
off label use181.30.81

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.